Carrier Michel, Moriguchi Jaime, Shah Keyur B, Anyanwu Anelechi C, Mahr Claudius, Skipper Eric, Cossette Mariève, Noly Pierre-Emmanuel
Department of Cardiac Surgery, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada.
Department of Cardiology, Cedars-Sinai (Smidt) Heart Institute, Los Angeles, California.
J Heart Lung Transplant. 2021 Mar;40(3):220-228. doi: 10.1016/j.healun.2020.11.012. Epub 2020 Nov 28.
We sought to assess the outcomes after heart transplantation (HT) of patients supported with a temporary total artificial heart (t-TAH) as a bridge to transplantation in high-volume centers.
A retrospective analysis of 217 consecutive patients who underwent t-TAH (SynCardia Systems, Tucson, Arizona) implantation between January 2014 and May 2019 in 6 high-volume North American centers was performed. End points included survival and adverse events after t-TAH and HT.
The mean age of patients was 49 ± 12 years, and heart failure etiologies were non-ischemic dilated cardiomyopathy (36%), ischemic (25%), restrictive (12%), and cardiac graft failure (9%). A total of 101 (48%) patients had Interagency Registry for Mechanically Assisted Circulatory Support patient profile 1, and 65 (31%) had Interagency Registry for Mechanically Assisted Circulatory Support patient profile 2. At the end of the study period, 138 of 217 (63.5%) patients had undergone HT, and 75 (34.5%) patients died before HT. The mean time between t-TAH implantation and HT averaged 181 ± 179 days (range: 0-849) and the mean follow-up after HT was 35 ± 25 months. The overall survival in the entire cohort was 75%, 64%, and 58% at 1, 2, and 5 years, respectively. Post-transplant survival was 88%, 84%, 79%, and 74% at 6 months, 1 year, 2 years, and 5 years, respectively. Among the 32 patients (23%) who died after HT, the main causes of death were chronic allograft vasculopathy (25%), multiorgan failure (21.8%), sepsis (15.6%), and stroke (9%).
In this multicenter study, almost two thirds of patients implanted with a t-TAH could be transplanted. The overall and post-transplantation survival after t-TAH was satisfactory in these critically ill patients.
我们试图评估在大容量中心接受临时全人工心脏(t-TAH)作为移植桥梁支持的患者心脏移植(HT)后的结局。
对2014年1月至2019年5月期间在北美6个大容量中心连续接受t-TAH(SynCardia Systems,图森,亚利桑那州)植入的217例患者进行回顾性分析。终点包括t-TAH和HT后的生存率及不良事件。
患者的平均年龄为49±12岁,心力衰竭病因包括非缺血性扩张型心肌病(36%)、缺血性(25%)、限制性(12%)和心脏移植失败(9%)。共有101例(48%)患者具有机构间机械辅助循环支持注册患者档案1,65例(31%)患者具有机构间机械辅助循环支持注册患者档案2。在研究期结束时,217例患者中有138例(63.5%)接受了HT,75例(34.5%)患者在HT前死亡。t-TAH植入与HT之间的平均时间为181±179天(范围:0-849天),HT后的平均随访时间为35±25个月。整个队列的1年、2年和5年总生存率分别为75%、64%和58%。移植后6个月、1年、2年和5年的生存率分别为88%、84%、79%和74%。在HT后死亡的32例患者(23%)中,主要死亡原因是慢性移植血管病(25%)、多器官衰竭(21.8%)、败血症(15.6%)和中风(9%)。
在这项多中心研究中,几乎三分之二植入t-TAH的患者能够接受移植。在这些重症患者中,t-TAH后的总体生存率和移植后生存率令人满意。